Compare BLND & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLND | XOMA |
|---|---|---|
| Founded | 2012 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.1M | 308.6M |
| IPO Year | 2021 | N/A |
| Metric | BLND | XOMA |
|---|---|---|
| Price | $1.43 | $36.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $4.13 | ★ $60.60 |
| AVG Volume (30 Days) | ★ 4.8M | 109.9K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $123,585,000.00 | N/A |
| Revenue This Year | $13.15 | $24.59 |
| Revenue Next Year | $14.17 | N/A |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.41 | $20.00 |
| 52 Week High | $4.49 | $39.92 |
| Indicator | BLND | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 36.27 | 84.37 |
| Support Level | N/A | $23.96 |
| Resistance Level | $1.94 | $39.46 |
| Average True Range (ATR) | 0.15 | 1.52 |
| MACD | -0.01 | 0.57 |
| Stochastic Oscillator | 1.55 | 100.00 |
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.